Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Https://twitter.com/Perspective_Tx/status/1787525768718717298
Fap, a pan cancer target. Indeed, it is.
Incidentally this company is doing rather well with its own tumour targeting product, with a 700% rise since December:
https://www.globenewswire.com/news-release/2023/06/21/2691937/0/en/Perspective-Therapeutics-Initiates-Phase-1-2a-Clinical-Trials-for-Two-Targeted-Alpha-Therapy-Oncology-Product-Candidates.html
This is an excellent comparison. Perspective Tx started their Phase 1 last year and the first results were out in late 2023 or early 2024. The first cohort had a decent safety profile and the SDMC recommended to move on to the 2nd dose cohort in mid-Jan 2024. Since then, the SP has gained ~300%. The platform was partially proven, hence the investment was significantly de-risked so the SP grew. This is the problem with AIM, such rational responses are simply not seen.
The only real difference that I can see is that Perspective Tx does seem to present at nearly every health/oncology conference under the sun. Whereas, Avacta appear to be very conservative on where/when to present.
We need a NASDAQ listing.
Boosters! Putting themselves out there, telling people what they're doing and advertising their progress!
I'd love to see Avacta start to do Nasdaq-style detailed quarterly reporting.
They have fast track designation on one drug which might explain the sp.
On the basis of this promising preclinical data, VMT-α-NET was awarded Fast Track designation under the FDA’s expedited development program
Hmmmm
Look more closely at their news flow
https://perspectivetherapeutics.com/newsroom/press-release?i=130069
Strategic agreement and investment in January plus couple of further dilutive raises shortly after totalling 50% is dilution ( I've not done the exact numbers )
It's the way they do it in US they raise and dilute ti increase the overall pie.
The AVCT model upto now has been to try and minimise dilution - there are pros and cons of each method.
Ultimately the moment of truth for either method is when external investment interest from BP is attracted - the jurys out on that at the moment, but maybe not for too much longer.
AS's strategy was in effect to not boost the Sp which was pretty much down to two factors ...1) That Avacta was 'his' company and...2) The disregard he had for the SH base.......I hoping that the new direction that Avacta are taking has amongst other things on its to do list.....some SP boosting
i wonder how much of all the “not boosting” ****** was the worm tongue (tp) whispering to him that his company is too expensive and should raise through their grubby little wonga book of “top quality” investors.
If anyone remains in doubt about the disruptive and worthless contributions of Wyn , Eggy & Touk
It is very telling that they have made zero contribution to the single most interesting and relevant thread posted here for days., thanks GJE, JT etc
Sadly, this board has lost many decent posters as they are drowned out by repetitive, pointless, boring, dull nonsense from the three stooges.
PS WYN, I'd prefer that you report this post and get it deleted as opposed to another boring 'stop picking on me, I was right about the LFT' essays.
I don't care what you say just that your logic in continually castigating me and projecting false accusations at me is somewhat confounded by the FACTS
If you are talking about the shortlisting award? Well, AVCT have been nominated twice before and not won so I don't quite yet see the significance.
If they win it then great, but that will be new news and then i can see if it materially changes anything. Right now for me, it doesn't.
You think 3 posters are the reason this BB is rubbish? Not the fact that the decent posters have been 100% wrong in every forecast they have made might be the cause and can't face the fair criticism of their misplaced analysis?
How has my analysis been worthless by the way? What contribution have you made that was so valuable?
It's a company that's doing something similar ie FAP and it's share price has recently done rather well.
Spiked to a similar height 3 years ago before falling back to baseline.
You're right Donald, fascinating, your point being?
Perhaps their tech is working and Avacta's isn't?
Is that what you're wanting to emphasise?
Many seem to forget this is an open BB that hosts individuals in both camps, the mere fact one camp is currently losing traction is rather more down to the Company’s actions than any individual. Disagreement is healthy if kept civilised !
JT great post. I think one of the biggest issues we have suffered from for years under AS is a lack of commitment on the PR front and an unwillingness to see the SP higher due to funding. It is as clear as day to me that his plan was to fly under the radar with the aim of building value, going through the trials before too many BP noticed. This has created several issues
1. Limits his options on funding which as we have found out has had very negative consequences and each of there last placings has been lower than the one before it.
2. Retail have shouldered most of the risk for that plan if indeed that was the case (I believe it was) and sentiment is shot and almost all are out of the money at sub 50p.
3. Lack of stability in the SP and a poor share register
4. Relying on the loan note to suppress the SP so funding could be achieved as he spent too long listening to the brokers in his ear
5. P1A has taken far too long with no efforts to expedite some areas ie why couldn't Q2W start at 160mg/m2 in parallel to Q3W dosing much higher cohorts?
6. This approach has cost him his job
Now AS is out the way a completely different approach can be taken. We absolutely should see positive reactions to newsflow, non dilutive options prioritised and striking deals. This isn't about the 6k trial now time to adjust the optics to think much bigger.
Rambo
Excellent analysis and one of the reasons I read this BB
Rambo, good summary of Alan's approach, why would he change it when it's funding his lifestyle. I disagree that right now they should look too far beyond ava6k.
They have a lovely poster, brochures available, for affimers calling out why they're superior. It's achieved nothing. They could produce the same for precision, now rebranded for a comparison against ADCs, showing how great the platform is. They need a commercial product out there proving it. Switching the pipeline to compete with ADCs isn't cheap, they're spending a lot on R&D. Personally I'd rather see them do that once they're self sustaining rather than diluting.
Hi Rambo, thanks for your thoughts.
I am not sure I agree with it all though.
I don't see any circumstantial proof to suggest he wanted AVCT to be under the radar. Although we have lamented the PR the fact we had Science days, several interviews, exhibition presentations, moving offices to become higher profile and very good data reported in the RNS's over the last 18 months or so, suggests to me that AVCT were in fact desperately trying to gather visibility.
I think the constant unpredicted delay in finishing (for whatever reason), various stages of the trial is the main reason why funding then became front and centre. (I think it was the "unexpected surprise" of having to gear up again after the 4th cohort that was pivotal as it added over a year on top of already slipping timelines.)
Can't argue with point 2&3! (but I think it was an inevitable consequence of the above)
I don't think the loan was any sort of master stroke to supress the SP. (The "we are overvalued to our peers" remark came way after that as the consequences of the delays and thus needing more funding, became crystal clear.)
Point 5: Well, that to me is the cause of all the reasons why the SP has collapsed to value it is now.
Point 6: I don't know, you may well be correct but the thing that makes me think it might not be, is that we are about to get 2WD first update, which really should be very good in both confirming how well it works and that shorter intervals between doses is more effective, so double good news, possibly the best news in AVCT history. To be able to produce that info fairly soon makes his departure right now seem a bit odd to me.
But hey ho, it is what it is.
Yes that's what's needed.
Consistent tumour responses in the two week arm without excessive side effects.
If it's as good as Dox and fewer/minimal side effects then the Share Price should react very well.
Even if it's not quite as good as Standard Dox but can be given for longer or in frailer patients it'll have a large roll and then Avacta can move on to equipping Pre|Cision with more powerful warheads.
Yet to confirm the move on from the 1st Cohort of the 2 week arm however so a little longer to go.
3-6 months minimum?
The 3rd patient in the 1st Cohort was dosed 3 months after the 1st!
Getting there slowly, very slowly.
If we're going for the conjecture sweepstakes on AS's dismissal, then here we go:
It is fairly routine for start ups to have their board removed shortly after they IPO or large investors get on board when the company is moving out of the start up phase, as they're often seen as blockers. They may be very good at coming up with the initial idea and getting that off the ground, but they often don't have the skills required to scale or commercialise. Not only that they can be emotionally attached to their baby, or still in ideas mode, losing focus on pushing through their original good idea.
I also think that AS has been led by the nose by Turner Pope et al. When they called me up they seemed to want to stress the special relationship they've had with AS over the years. Yes, special in that they can squeeze his nuts from time to time and make a killing.
All in all, the last raise, the distraction and diversion of the dx venture, which would have made even truss proud, were the last straw, and shareholders had enough. After all 19 years is long enough for a start up to emerge from the incubator. Ironically that last dilution might have been some desperate last attempt to alter the register in his favour to save his bacon.
There is nothing yet to tell us that the 2w arm will take another 6 months from now, but agree an update on this would help restore sentiment.